Rocket Pharmaceuticals Inc (RCKT)

$3.14 0.00 (N/A)
Market Cap 342.87M
Revenue (ttm) 0.00
Net Income (ttm) -223.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,131,700
Avg Vol 2,506,052
Day's Range N/A - N/A
Shares Out 109.19M
Stochastic %K 21%
Beta 0.45
Analysts Sell
Price Target $8.98

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogeni...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 659 8001
Address:
9 Cedarbrook Drive, Cranbury, United States
Tunes444
Tunes444 Jul. 30 at 1:14 PM
$RCKT last piece of news from back on June 12th 'Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million'
0 · Reply
InvitationW
InvitationW Jul. 29 at 2:28 PM
$RCKT Multiple drugs right?
0 · Reply
Risk1123
Risk1123 Jul. 28 at 1:06 PM
$RCKT Also trying to figure this out!!
2 · Reply
Resilience1239
Resilience1239 Jul. 27 at 9:52 PM
$RCKT COME ON! When is our next Catalyst?????
0 · Reply
Tunes444
Tunes444 Jul. 27 at 12:31 PM
$RCKT this.
0 · Reply
Resilience1239
Resilience1239 Jul. 26 at 3:23 AM
$RCKT When is our last pump to $7-$8 before the entire stock market crash comes......
0 · Reply
Merlintrader
Merlintrader Jul. 25 at 1:34 PM
$RCKT $DNLI $XBI $IBB
0 · Reply
Kavya_Das27382
Kavya_Das27382 Jul. 23 at 8:12 PM
$RCKT just followed this one
0 · Reply
EKingsler
EKingsler Jul. 23 at 8:12 PM
$RCKT
0 · Reply
Prazzclatt
Prazzclatt Jul. 23 at 5:37 PM
$RCKT turned that Priority Review Voucher into $180M cash, no dilution, runway now into Q2 2028 👀
0 · Reply
Latest News on RCKT
Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M

2026-06-12T11:05:45.000Z - 6 weeks ago

Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Jun 12, 2026, 7:00 AM EDT - 6 weeks ago

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Rocket Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 7 weeks ago

Rocket Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Rocket Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 8:10 AM EDT - 2 months ago

Rocket Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Rocket Pharmaceuticals price target raised to $10 from $9 at BofA

2026-06-03T15:27:07.000Z - 2 months ago

Rocket Pharmaceuticals price target raised to $10 from $9 at BofA

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

May 28, 2026, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals Transcript: AGM 2026

May 20, 2026, 9:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Transcript: AGM 2026

Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)

2026-05-07T21:49:50.000Z - 2 months ago

Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 7, 2026, 4:00 PM EDT - 2 months ago

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Quarterly report: Q1 2026

Rocket Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Earnings release: Q1 2026

Rocket Pharmaceuticals announces $180M sale of priority review voucher

2026-04-28T11:29:11.000Z - 3 months ago

Rocket Pharmaceuticals announces $180M sale of priority review voucher

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Apr 28, 2026, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

Rocket Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

Rocket Pharmaceuticals price target raised to $9 from $8 at BofA

2026-03-30T10:30:11.000Z - 4 months ago

Rocket Pharmaceuticals price target raised to $9 from $8 at BofA

Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink

2026-03-27T19:15:17.000Z - 4 months ago

Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink

PRV reception could net Rocket $100M-$200M, says LifeSci Capital

2026-03-27T16:13:26.000Z - 4 months ago

PRV reception could net Rocket $100M-$200M, says LifeSci Capital

Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush

2026-03-27T16:10:33.000Z - 4 months ago

Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush

Rocket Pharmaceuticals Transcript: FDA announcement

Mar 27, 2026, 8:30 AM EDT - 4 months ago

Rocket Pharmaceuticals Transcript: FDA announcement

Rocket Pharmaceuticals Press release: FDA announcement

Mar 27, 2026, 8:30 AM EDT - 4 months ago

Rocket Pharmaceuticals Press release: FDA announcement

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

Mar 27, 2026, 7:27 AM EDT - 4 months ago

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

Rocket Pharmaceuticals announces FDA approval of Kresladi

2026-03-27T11:05:10.000Z - 4 months ago

Rocket Pharmaceuticals announces FDA approval of Kresladi

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Mar 27, 2026, 7:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

FDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I

2026-03-27T00:55:09.000Z - 4 months ago

FDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I

Rocket Pharmaceuticals Proxy statement: Proxy filing

Mar 25, 2026, 8:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

Rocket Pharmaceuticals offers to sell up to $100M in common stock

2026-03-10T21:40:14.000Z - 5 months ago

Rocket Pharmaceuticals offers to sell up to $100M in common stock

Rocket Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 9:20 AM EDT - 5 months ago

Rocket Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Rocket Pharmaceuticals files $400M mixed securities shelf

2026-03-02T21:21:06.000Z - 5 months ago

Rocket Pharmaceuticals files $400M mixed securities shelf

Rocket Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:10 AM EST - 5 months ago

Rocket Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Rocket Pharmaceuticals Registration statement: Registration Filing

Mar 2, 2026, 7:00 AM EST - 5 months ago

Rocket Pharmaceuticals Registration statement: Registration Filing

Rocket Pharmaceuticals price target raised to $3 from $2 at Goldman Sachs

2026-03-02T11:54:20.000Z - 5 months ago

Rocket Pharmaceuticals price target raised to $3 from $2 at Goldman Sachs

Rocket Pharmaceuticals price target raised to $10 from $8 at Cantor Fitzgerald

2026-02-27T15:05:34.000Z - 5 months ago

Rocket Pharmaceuticals price target raised to $10 from $8 at Cantor Fitzgerald

Rocket Pharmaceuticals reports Q4 EPS (38c), consensus (42c)

2026-02-26T21:17:28.000Z - 5 months ago

Rocket Pharmaceuticals reports Q4 EPS (38c), consensus (42c)

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Feb 26, 2026, 4:00 PM EST - 5 months ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 5 months ago

Rocket Pharmaceuticals Earnings release: Q4 2025

Rocket Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 5 months ago

Rocket Pharmaceuticals Annual report: Q4 2025

Rocket Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 2:15 PM EST - 7 months ago

Rocket Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals price target lowered to $5 from $7 at Morgan Stanley

2026-01-08T12:46:26.000Z - 7 months ago

Rocket Pharmaceuticals price target lowered to $5 from $7 at Morgan Stanley

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 7 months ago

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 7:55 AM EST - 8 months ago

Rocket Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 8 months ago

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 6, 2025, 4:00 PM EST - 9 months ago

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Rocket Pharmaceuticals Earnings release: Q3 2025

Rocket Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Rocket Pharmaceuticals Quarterly report: Q3 2025

Rocket Pharmaceuticals Slides: Corporate Presentation

Nov 6, 2025, 7:00 AM EST - 9 months ago

Rocket Pharmaceuticals Slides: Corporate Presentation

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Oct 14, 2025, 7:00 AM EDT - 10 months ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2025, 4:00 PM EDT - 10 months ago

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Oct 3, 2025, 7:11 AM EDT - 10 months ago

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Rocket Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 9:15 AM EDT - 11 months ago

Rocket Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Rocket Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:20 PM EDT - 11 months ago

Rocket Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 11:02 AM EDT - 1 year ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:09 AM EDT - 1 year ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 20, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 8, 2025, 2:16 PM EDT - 1 year ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rocket Pharmaceuticals Earnings release: Q2 2025

Rocket Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rocket Pharmaceuticals Quarterly report: Q2 2025

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 24, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 17, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jul 9, 2025, 5:16 PM EDT - 1 year ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Tunes444
Tunes444 Jul. 30 at 1:14 PM
$RCKT last piece of news from back on June 12th 'Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million'
0 · Reply
InvitationW
InvitationW Jul. 29 at 2:28 PM
$RCKT Multiple drugs right?
0 · Reply
Risk1123
Risk1123 Jul. 28 at 1:06 PM
$RCKT Also trying to figure this out!!
2 · Reply
Resilience1239
Resilience1239 Jul. 27 at 9:52 PM
$RCKT COME ON! When is our next Catalyst?????
0 · Reply
Tunes444
Tunes444 Jul. 27 at 12:31 PM
$RCKT this.
0 · Reply
Resilience1239
Resilience1239 Jul. 26 at 3:23 AM
$RCKT When is our last pump to $7-$8 before the entire stock market crash comes......
0 · Reply
Merlintrader
Merlintrader Jul. 25 at 1:34 PM
$RCKT $DNLI $XBI $IBB
0 · Reply
Kavya_Das27382
Kavya_Das27382 Jul. 23 at 8:12 PM
$RCKT just followed this one
0 · Reply
EKingsler
EKingsler Jul. 23 at 8:12 PM
$RCKT
0 · Reply
Prazzclatt
Prazzclatt Jul. 23 at 5:37 PM
$RCKT turned that Priority Review Voucher into $180M cash, no dilution, runway now into Q2 2028 👀
0 · Reply
Tunes444
Tunes444 Jul. 23 at 1:59 PM
$RCKT This guy is spitting rn
0 · Reply
Risk1123
Risk1123 Jul. 22 at 7:34 PM
$RCKT
0 · Reply
BobBijawklah
BobBijawklah Jul. 22 at 7:13 AM
$RCKT love the sale of the voucher . Essentially this stock has one approved drug and 2 and change in cash per share. Low risk. Great point for me to reinvest. To me this is a no brainer.
1 · Reply
EzGuap
EzGuap Jul. 21 at 4:35 PM
$RCKT love a biotech that has cash (legit almost as much as the current mc) and wont do the GME ATM Strat on our heads
0 · Reply
Tunes444
Tunes444 Jul. 21 at 1:23 PM
$RCKT Just started following this one!
0 · Reply
Risk1123
Risk1123 Jul. 21 at 1:07 PM
$RCKT what should i be expecting??
1 · Reply
KiingDrew
KiingDrew Jul. 21 at 1:04 PM
$RCKT isn't hoping for one big catalyst, they've got several trial readouts stacked up over the next year
0 · Reply
DiamondHandsHarold
DiamondHandsHarold Jul. 21 at 1:02 PM
$RCKT
0 · Reply
Merlintrader
Merlintrader Jul. 20 at 8:25 PM
Priority Review Voucher explainer: $RCKT and $DNLI turned one FDA approval into $180-205M cash. Relevant for $XBI and $IBB biotech investors. https://www.merlintrader.com/priority-review-voucher-explained-rckt-dnli-2026/
0 · Reply
canuck_trader92
canuck_trader92 Jul. 20 at 2:48 PM
$RCKT just landed $180M by selling their priority review voucher, extending cash runway into 2028
0 · Reply
diamonhands72
diamonhands72 Jul. 17 at 8:44 PM
$RCKT
0 · Reply
Magnificent77
Magnificent77 Jul. 17 at 5:55 PM
$RCKT this thing is still trading at such a discount from where it was, with one already approved drug it blows my mind its valuation is here...
1 · Reply